Latest News - Pain & Headache

Tuesday, April 18, 2017 | FDA Approval/Clearance, Pain & Headache

FDA Releases Non-Invasive VNS Therapy for Pain Associated with Episodic Cluster Headache

The FDA has released the use of gammaCore, a non-invasive vagus nerve stimulator for the acute treatment of pain associated with episodic cluster headache in adult patients. gammaCore transmits a mild…

Read the full story

Thursday, March 30, 2017 | FDA Approval/Clearance, Pain & Headache

FDA Approves Expanded Indication For Qudexy XR Extended Release Capsules

The FDA has approved two supplemental indications for Qudexy XR (topiramate, Upsher-Smith) Extended Release Capsules for use as prophylaxis of migraine headache in adults and adolescents 12 years of a…

Read the full story

Friday, March 24, 2017 | Epilepsy & Seizure Disorders, Pain & Headache, Research and Publications

Review Identifies Antidepressants and AEDs Effective for Nerve Pain

A federal health agency has found certain antidepressants and anti-seizure drugs are among medications that effectively treat diabetic nerve pain. In findings published in the journal Neurology, resea…

Read the full story

Thursday, January 19, 2017 | Pain & Headache, Research and Publications

Lower Vitamin D Levels in Men Linked to Increased Frequency of Headache

Low levels of vitamin D was associated with markedly higher risk of frequent headache in men, according to new findings published in Scientific Reports (Article number: 39697, 2017). Investi…

Read the full story

Wednesday, January 18, 2017 | Acquisitions and Mergers, Pain & Headache, Personnel/Company News

Lilly to Acquire Migraine Drug Maker CoLucid

Eli Lilly and Co. is set to acquire CoLucid Pharmaceuticals for $960 million. CoLucid is currently developing lasmiditan, a migraine medicine that could help patients with cardiovascular disease.…

Read the full story

Thursday, November 17, 2016 | Pain & Headache, Phase 3/4 Trials, Phase 3/4 Trials, Research and Publications

Investigational Biologic for the Treatment of Migraine Shows Promise in Phase 3 Data

New Phase 3 trial results suggest that Amgen’s investigational biologic agent erenumab may be effective at reducing migraines. Erenumab was specifically designed to prevent migraine by bloc…

Read the full story

Tuesday, November 15, 2016 | FDA Approval/Clearance, Pain & Headache

New MRI Labeling Approved for St. Jude Medical’s SCS System

The FDA has approved new labeling for full-body magnetic resonance imaging (MRI) for St. Jude Medical’s Proclaim Elite Spinal Cord Stimulation (SCS) System. The new labeling ensures patients in …

Read the full story

Monday, October 24, 2016 | Pain & Headache, Research and Publications

Oral Bacteria Linked to Migraine

Oral bacteria that convert nitrates into nitric oxide in the blood may be the key to understanding the cause of migraines, according to newly published findings. In a study published in mSystems from …

Read the full story

Wednesday, October 05, 2016 | FDA Approval/Clearance, Pain & Headache

FDA Greenlights Spinal Cord Stimulation Therapy for Patients with Chronic Pain

The FDA has approved BurstDR stimulation, a physician-designed form of spinal cord stimulation (SCS) for patients with chronic pain. According to manufacturer St. Jude Medical, BurstDR helps phys…

Read the full story